Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Rapamycin Protects Against Peritendinous Fibrosis Through Activation of Autophagy.

Zheng W, Qian Y, Chen S, Ruan H, Fan C.

Front Pharmacol. 2018 Apr 20;9:402. doi: 10.3389/fphar.2018.00402. eCollection 2018.

2.

hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.

Passacantilli I, Frisone P, De Paola E, Fidaleo M, Paronetto MP.

Nucleic Acids Res. 2017 Dec 1;45(21):12270-12284. doi: 10.1093/nar/gkx831.

3.

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.

Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG.

Oncotarget. 2017 Apr 4;8(14):23851-23861. doi: 10.18632/oncotarget.12904.

4.

Potential approaches to the treatment of Ewing's sarcoma.

Yu H, Ge Y, Guo L, Huang L.

Oncotarget. 2017 Jan 17;8(3):5523-5539. doi: 10.18632/oncotarget.12566. Review.

5.

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA.

J Natl Cancer Inst. 2016 Aug 30;108(12). pii: djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec.

6.

Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance.

Ahmed AA, Abedalthagafi M, Anwar AE, Bui MM.

J Cancer. 2015 Aug 22;6(10):1005-10. doi: 10.7150/jca.12703. eCollection 2015.

7.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

8.

Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.

Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC.

Mol Biol Cell. 2014 Sep 15;25(18):2695-709. doi: 10.1091/mbc.E14-01-0007. Epub 2014 Jul 23.

9.

Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.

Elzi DJ, Song M, Hakala K, Weintraub ST, Shiio Y.

J Proteome Res. 2014 Aug 1;13(8):3783-91. doi: 10.1021/pr500387m. Epub 2014 Jul 14.

10.

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.

Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.

Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874. Epub 2013 Nov 19.

11.

A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.

Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn RH, Liem B, Bocklage T, Shaheen M.

Cancers (Basel). 2013 Apr 11;5(2):418-29. doi: 10.3390/cancers5020418.

12.

The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.

Sengupta A, Rahman M, Mateo-Lozano S, Tirado OM, Notario V.

Int J Oncol. 2013 Sep;43(3):803-12. doi: 10.3892/ijo.2013.2016. Epub 2013 Jul 12.

13.

Potential molecular targets for Ewing's sarcoma therapy.

Jully B, Rajkumar T.

Indian J Med Paediatr Oncol. 2012 Oct;33(4):195-202. doi: 10.4103/0971-5851.107074.

14.

Microsatellite instability in sarcoma: fact or fiction?

Monument MJ, Lessnick SL, Schiffman JD, Randall RT.

ISRN Oncol. 2012;2012:473146. doi: 10.5402/2012/473146. Epub 2012 Jul 18.

15.

Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.

Keedy VL.

Onco Targets Ther. 2012;5:153-60. doi: 10.2147/OTT.S19055. Epub 2012 Aug 22.

16.

Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.

Kelleher FC, Thomas DM.

Clin Sarcoma Res. 2012 Feb 1;2(1):6. doi: 10.1186/2045-3329-2-6.

17.

Treatment of Bone Tumors.

Rajani R, Gibbs CP.

Surg Pathol Clin. 2012 Mar;5(1):301-18. doi: 10.1016/j.path.2011.07.015.

18.

Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Dai X, Ma W, He X, Jha RK.

Med Sci Monit. 2011 Aug;17(8):RA177-190. Review.

19.

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.

Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR.

Sarcoma. 2011;2011:402508. doi: 10.1155/2011/402508. Epub 2011 May 3.

20.

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.

Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R.

PLoS One. 2011 Apr 6;6(4):e18424. doi: 10.1371/journal.pone.0018424.

Supplemental Content

Support Center